FDMT FY 2018 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$427M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+144.0% YoY

Gross Profit

-$4M-30.0% margin

Operating Income

-$10M-73.6% margin

Net Income

-$10M-67.6% margin

EPS (Diluted)

$-0.76

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$97M

Total Liabilities

$125M

Stockholders' Equity

-$28M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$6M	+144.0%
Gross Profit	-$4M	-$8M	+45.6%
Operating Income	-$10M	-$11M	+7.7%
Net Income	-$10M	-$11M	+14.9%